ABSTRACT
The influence of 2 different cardiac pharmaceutics on the diastolic ventricular function (VF) in patients with ischaemic heart disease was examined. Diltiazem, a calcium antagonist, and k-strophanthine led to a reduction of time constant T of the isovolumic relaxation from 49 +/- 9 to 39 +/- 7 msec (p less than 0.005), to an increase of the quotient dt/T from 2.4 +/- 0.5 to 3.0 +/- 0.6 msec (p less than 0.01), to an increase of the peak filling rate (PFR) from 2.08 +/- 0.65 EDV/sec to 2.34 +/- 0.67 EDV/sec (p less than 0.001), to an increase of the filling fraction (FF) from 30 +/- 12% to 33 +/- 15% (p less than 0.001). The ejection fraction (EF) and the maximum rise of pressure dp/dt did not change significantly. After k-strophanthine T was reduced from 49 +/- 7 to 46 +/- 11 msec (p less than 0.05). The increase of dt/T from 2.5 +/- 0.4 to 2.7 +/- 0.4 msec was not significant. The PFR with 2.16 +/- 0.7 and 2.08 +/- 0.8 EDV/sec and the FF with 32 +/- 14 and 34 +/- 18% did not show any significant changes. The EF rose from 52 +/- 15 to 55 +/- 16 (p less than 0.05) and dp/dt rose from 1855 +/- 468 to 2124 +/- 591 (p less than 0.05). Diltiazem improves the diastolic VF without deteriorating the systolic VF in patients with ischaemic heart disease. K-strophanthine improves the systolic VF and the velocity of the isovolumic relaxation. The other variables of the diastolic VF did not show any directed changes.
Subject(s)
Coronary Disease/drug therapy , Cymarine/therapeutic use , Diltiazem/therapeutic use , Myocardial Contraction/drug effects , Strophanthins/therapeutic use , Adult , Blood Pressure/drug effects , Cardiac Catheterization , Diastole/drug effects , Humans , Middle Aged , Stroke Volume/drug effectsABSTRACT
A new combined modality treatment in advanced squamous cell carcinoma of the head and neck, is presented. It consists of surgery, or radiotherapy, followed by adjuvant chemotherapy with MTX and CF rescue, cis-DDP, Bleomycin, Cyclophosphamide, given sequentially. Toxic effects were not very severe and did not cause an interruption of therapy.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Head and Neck Neoplasms/drug therapy , Bleomycin/therapeutic use , Cisplatin/therapeutic use , Cyclophosphamide/therapeutic use , Drug Therapy, Combination , Humans , Leucovorin/therapeutic use , Methotrexate/therapeutic useABSTRACT
27 patients with a mean cumulative dose of 450 +/- 150 mg adriamycin for the treatment of solid malignoma and clinical symptoms of left heart failure are examined by echocardiography. 14 patients had an abnormal ejection fraction, 21 patients an abnormal mean circumferential fiber shortening and 4 patients presented with pericardial effusion. The results demonstrate that echocardiography is a safe, noninvasive and reliable method for diagnosing a reduced left ventricular function in patients treated with adriamycin.
